Education
About Us
Working with TipRanks
Follow Us
Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
DWTX Stock Chart & Stats
$5.26
-$0.11(-4.15%)
At close: 4:00 PM EST
$5.26
-$0.11(-4.15%)
Day’s Range― - ―
52-Week Range$1.62 - $29.28
Previous CloseN/A
Volume14.38K
Average Volume (3M)1.54M
Market Cap
$12.06M
Enterprise Value$96.56M
Total Cash (Recent Filing)$13.40M
Total Debt (Recent Filing)$186.99K
Price to Earnings (P/E)―
Beta2.76
Next Earnings
Apr 06, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.20
Shares Outstanding2,293,162
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap8.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.60K
Enterprise Value/Ebitda-5.31
Forecast
1Y Price Target
$21.00Price Target Upside299.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Approvals And TrialsThe company has received FDA special protocol assessment (SPA) approval to conduct a Phase 3 registration-directed study of Halneuron in the U.S., Canada, and E.U.
Funding And Financial StrategyThe upcoming Phase 1b study for SP16 is fully funded through a grant, which reduces financial risk and burden on Dogwood Therapeutics.
Partnerships And LicensingDogwood announced an all-stock transaction to secure an exclusive global license for SP16, a peptide-based therapeutic for treatment of cancer-related pain from Serpin Pharma; shares rose 43% on the news.
Bears Say
Financial PerformanceThe company reported no revenues in the quarter and a net loss of $1.99 per share, which was worse than the consensus estimated net loss of $0.79 per share.
Operational LossesDogwood reported 3Q25 results with a net loss of ($15.7M), which included $12M in acquired in-process research and development expenses related to licensing SP16.
Revenue And Profitability ChallengesDogwood reported a net loss of $3.8M, which impacts its financial position.
Dogwood Therapeutics News
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $1.62 and its highest was $29.28 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $12.06M.
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 146 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on Nov 06, 2025. The company reported -$8.2 earnings per share for the quarter, missing the consensus estimate of -$1.16 by -$7.04.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate is -1.04.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 2,293,162 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$8.2 in its last earnings report, missing expectations of -$1.16. Following the earnings report the stock price went down -6.475%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
DWTX Stock 12 Month Forecast
Average Price Target
$21.00
▲(299.24% Upside)
Technical Analysis
Marker Therapeutics
―
BioRestorative Therapies
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
3.40%
Insiders
1.04% Mutual Funds
<0.01% Other Institutional Investors
94.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---